The technology upgrades of KINGSOFT CLOUD's Xingliu platform and other products have driven rapid growth in AI cloud services. KINGSOFT CLOUD (03896) has achieved a record high in overall revenue for Q2.
Kingsoft Cloud's Q2 revenue reached 3.07 billion yuan, setting a new single-quarter historical record and representing a year-on-year growth of 30.8%. During the quarter, AI cloud billing revenue amounted to 1.33 billion yuan, a year-on-year increase of 82%.
On August 19, KINGSOFT CLOUD (KC.US, 03896) released its Q2 2026 financial report. The report shows that KINGSOFT CLOUD's Q2 revenue reached 3.07 billion yuan, setting a new record for quarterly revenue, with a year-on-year increase of 30.8%. During the quarter, AI cloud billing revenue reached 1.33 billion yuan, a year-on-year increase of 82%, accounting for 56% of public cloud revenue, which drove public cloud revenue up 45.1% year-on-year to 2.36 billion yuan.
With an optimized revenue structure and effective cost-reduction and efficiency-enhancement measures, KINGSOFT CLOUD's profitability has continued to improve, with Q2 adjusted gross margin increasing to 15.4%, up 2.4 percentage points quarter-on-quarter; the adjusted operating profit margin reached 4.0%, achieving operating-level profitability once again.
KINGSOFT CLOUD is closely focused on the demand for intelligent computing deployment and AI applications, upgrading its full-stack AI capabilities. In this quarter, KINGSOFT CLOUD's Xingyuan AgentKit platform provides a one-stop development and governance foundation for enterprise-level AI applications, integrating runtime, secure sandbox, knowledge, and memory capabilities to help enterprises quickly build production-grade AI agent applications; KINGSOFT CLOUD's Xingliu model API services upgraded to provide multi-model services and enterprise-level access capabilities, with core model throughput capacity improved by approximately 150% through high-concurrency inference optimization, and supporting full-link refined management by permissions, usage, and model dimensions.
Related Articles

US Stock Market Move | Merck & Co., Inc. (MRK.US) and Moderna (MRNA.US) both saw their stock prices soar! The phase III trial of the personalized mRNA cancer vaccine was successful.

CONTINENTAL H (00513) plans to sell all shares of IQ Group for HKD 85 million, resuming trading on August 20.

Jiangsu Hengrui Pharmaceuticals (01276): Liu Xiaohan resigns as joint company secretary.
US Stock Market Move | Merck & Co., Inc. (MRK.US) and Moderna (MRNA.US) both saw their stock prices soar! The phase III trial of the personalized mRNA cancer vaccine was successful.

CONTINENTAL H (00513) plans to sell all shares of IQ Group for HKD 85 million, resuming trading on August 20.

Jiangsu Hengrui Pharmaceuticals (01276): Liu Xiaohan resigns as joint company secretary.

RECOMMEND





